

# ASTRAZENECA PLC

ISIN: GB0009895292 WKN: 0989529 Asset Class: **Stock**

## Company

2024/07/12 17:35:26

Price  
**12,260.00**

GBP

Difference ▲  
1.32% (160.00)



## Contact Details

ASTRAZENECA PLC  
--  
Cambridge Biomedical Campus,  
1 Francis Crick Avenue  
CB2 0AA Cambridge

Tel: +44-20-3749-5000  
Fax: +  
Web: <http://www.astrazeneca.co.uk>  
E-mail: -

## Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 19,653,278,000 |                        | 18,782,109,000 |                        | 19,376,130,000 |                        |
| <b>Common stock capital</b>           |                | 304,361,000            |                | 321,722,000            |                | 285,724,000            |
| <b>Fixed assets</b>                   | 59,668,183,000 |                        | 61,426,552,000 |                        | 58,414,116,000 |                        |
| <b>Equity capital of a company</b>    |                | 30,723,250,000         |                | 30,807,215,000         |                | 29,005,869,000         |
| <b>Cash and cash equivalents</b>      | 4,581,110,000  |                        | 5,125,945,000  |                        | 4,672,745,000  |                        |
| <b>Accrued liabilities</b>            |                | 2,076,404,000          |                | 1,715,853,000          |                | 2,517,627,000          |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 23,958,267,000         |                | 21,858,009,000         |                | 16,681,309,000         |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 24,639,943,000         |                | 27,543,436,000         |                | 32,103,067,000         |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 2,116,410,000          |                | 3,686,091,000          |                | 3,675,292,000          |
| <b>Total assets</b>                   | 79,321,462,000 | 79,321,462,000         | 80,208,662,000 | 80,208,662,000         | 77,790,246,000 | 77,790,246,000         |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | IFRS    | IFRS    | IFRS    |
| <b>Employees</b>           | 89,900  | 83,500  | 83,100  |
| <b>Equity ratio</b>        | 38.76%  | 38.43%  | 37.31%  |
| <b>Debt-equity ratio</b>   | 158.03% | 160.21% | 168.06% |

## Others

|                         | 2023   | 2022    | 2021    |
|-------------------------|--------|---------|---------|
| <b>Tax Expense Rate</b> | 13.57% | -31.60% | 189.05% |

## Income statement

|  | 2023           | 2022           | 2021           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 36,853,651,000 | 36,005,612,000 | 27,508,829,000 |
| <b>Net income</b>  | 4,790,628,000  | 2,669,307,000  | 81,436,000     |
| <b>EBIT</b>  | 7,399,327,758  | 3,195,067,240  | 483,985,044    |
| <b>Operating income before taxes</b>                                 | 5,559,703,000  | 2,034,453,000  | -146,149,000   |
| <b>Cash Flow</b>   | 8,553,142,000  | 8,011,169,000  | 4,360,490,000  |
| <b>Net interest income</b>   | -676,560,000   | -658,396,000   | -554,059,000   |
| <b>Research and development expenses</b>                             | 8,322,259,000  | 7,825,259,000  | 6,214,626,000  |
| <b>Income taxes</b>  | 754,594,000    | -642,971,000   | -276,302,000   |
| <b>Result from investments in subsidiaries, associates and other</b> | -9,653,000     | -4,059,000     | -46,535,000    |
| <b>Revenues per employee</b>   | 486,394        | 511,625        | 392,770        |

## Board of Directors

|                           |                               |
|---------------------------|-------------------------------|
| Michel Demaré             | Chairman of Supervisory Board |
| Andreas Rummelt           | Member of Supervisory Board   |
| Aradhana Sarin            | Member of Supervisory Board   |
| Euan Ashley               | Member of Supervisory Board   |
| Nazneen Rahman            | Member of Supervisory Board   |
| Shu Kam Mok               | Member of Supervisory Board   |
| Anna Olive Magdelene Manz | Member of Supervisory Board   |
| Deborah DiSanzo           | Member of Supervisory Board   |
| Diana Layfield            | Member of Supervisory Board   |
| Marcus Wallenberg         | Member of Supervisory Board   |
| Philip Broadley           | Member of Supervisory Board   |
| Sherilyn McCoy            | Member of Supervisory Board   |

## Members of Management Board

|                         |                               |
|-------------------------|-------------------------------|
| Pascal Soriot           | Chairman of Managing Board    |
| Aradhana Sarin          | Member of Executive Committee |
| Ruud Dobber             | Member of Executive Committee |
| David Fredrickson       | Member of Executive Committee |
| Iskra Reic              | Member of Executive Committee |
| Jeff Pott               | Member of Executive Committee |
| Leon Wang               | Member of Executive Committee |
| Marc Dunoyer            | Member of Executive Committee |
| Menelas (Mene) Pangalos | Member of Executive Committee |
| Pam Cheng               | Member of Executive Committee |
| Sharon Barr             | Member of Executive Committee |
| Susan Galbraith         | Member of Executive Committee |